Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon beta-1a vs glatiramer acetate in paediatric relapsing-remitting multiple sclerosis
2017-005129-18Phase 3Completed
- Sponsor
- University of Bari Aldo Moro
- Start
- Mar 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple sclerosis (MS) comparing Interferon beta-1a arm with Glatiramer acetate arm (2 arms). Primary endpoint: Proportion of subjects free of new or newly enlarging T2 lesions at 96 weeks. Started Mar 2018; status: completed.
02
Drugs
interferon beta-1aglatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-005129-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005129-18.